These results show that yeast hydrolysate with below 10 kDa molecular weight possesses very low toxicity as indicated in this SD rat model.”
“In this study, we
investigated the possibility of using local administration of allogeneic bone marrow mesenchymal stem cells (BMMSCs) to induce tissue regeneration in periodontal defects in a rat model of periodontitis. BMMSCs isolated from rats were mixed with 0.9% NaCl solution and injected into periodontal defects. Control groups were 0.9% NaCl solution or left untreated. The clinical assessments, x-rays, and histological examinations were used to evaluate the effect. At 12 wks post-transplantation, quantitative analysis revealed average probing bone loss values of 1.2 +/- 0.19, 1.6 +/- 0.2, and 1.7 +/- 0.14; the bone regeneration rate was 53%, 45%, and 44% in GSK 4529 the BMMSC+NaCl group, NaCl group, and untreated group, respectively. The clinical assessments, x-rays, and histological examinations revealed significant periodontal tissue regeneration in the BMMSC injection group, compared with the control groups. The ELISA results showed that TNF, IFN, and IL1
were 2,674.88 +/- 102.77 pg/mL vs. 3,422.1 +/- 51.98 BMS-777607 clinical trial pg/mL, 609.85 +/- 25.5 pg/mL vs. 803.79 +/- 33.85 pg/mL, and 1,038.46 +/- 76.29 pg/mL vs. 1,175.26 +/- 105.55 pg/mL in the BMMSC+NaCl group and NaCl group, respectively, indicating that BMMSC A-1210477 in vitro injection inhibited the inflammatory factors TNF, IFN, and IL1. Our results indicate that local administration of BMMSCs can repair
defects due to periodontitis, exerting anti-inflammatory and immunomodulatory functions.”
“A best evidence topic in thoracic surgery was written according to a structured protocol. The question addressed was ‘In pneumonectomy patients, is buttressing the bronchial stump associated with a reduced incidence of bronchopleural fistula?’. Fifty-seven papers were found using the reported search, of which 12 represented the best evidence to answer the clinical question. The authors, journal, date and country of publication, patient group studied, study type, relevant outcomes and results of these papers are tabulated. One prospective randomized controlled trial was identified, which found significantly lower rates of bronchopleural fistula and empyema after pneumonectomy with the use of pedicled intercostal flap buttressing. Intercostal muscle flaps and pericardial flaps have been used in case series of high-risk patients, e.g. those with neoadjuvant therapy or extended resections, with low rates of subsequent bronchopleural fistulae. There is the least-reported evidence for thoracodorsal artery perforator and omental flaps. There is relatively little published evidence beyond the single randomized trial identified, with only a few comparison studies to guide clinicians.